A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) with Pembrolizumab (MK-3475) in Selected Solid Tumors.
Primary:
Cohort A: To evaluate pathological complete response (pCR) rate of MK- 4280A or pembrolizumab as assessed by blinded central pathology review
Cohort B: To evaluate lenvatinib in combination with MK-4280A or pembrolizumab with respect to objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by investigator
Pembrolizumab (MK-3475)
- Rutgers Cancer Institute of New Jersey
- RWJBarnabas Health
- Community Medical Center
- Monmouth Medical Center Vantage Point Center
- Robert Wood Johnson University Hospital, Somerset
Inclusion Criteria
Cohort A only
- Histologically confirmed diagnosis of resectable cutaneous squamous cell carcinoma
(cSCC) as the primary site of malignancy (metastatic skin involvement from another
primary cancer or from an unknown primary cancer is not permitted)
- Stage II to Stage IV disease without distant metastasis (M1). cSCC tumors arising in
the head and neck will be staged according to American Joint Committee on Cancer
(AJCC) Edition (Ed.) 8 and cSCC tumors arising in non-head and neck locations will
be staged according to Union for International Cancer Control (UICC) Ed. 8
- Is systemic treatment naïve
- Archival tumor tissue sample, or newly obtained surgical resection, or biopsy sample
of a tumor lesion not previously irradiated has been provided
- Is an individual of any sex/gender, at least 18 years of age at the time of
providing the informed consent
Cohort B only
- Histologically confirmed diagnosis of endometrial cancer (EC) that is not deficient
in mismatch repair (dMMR) proficient in mismatch repair (pMMR) as documented by a
local test report
- Documented evidence of stage IVB (per 2009 International Federation of Gynecology
and Obstetrics (FIGO) staging), recurrent, or metastatic EC, and are not candidates
for curative surgery or radiation
- Has radiographic evidence of disease progression after 1 prior systemic,
platinum-based chemotherapy regimen for EC in any setting
- Measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST 1.1) by
investigator (before first dose of study intervention)
- Is assigned female sex at birth, at least 18 years of age at the time of providing
the informed consent
- Has adequately controlled blood pressure without antihypertensive medication
All Cohorts
- Agrees to follow contraception guidelines if a participant of childbearing potential
- Has a life expectancy >3 years per investigator assessment
- Has adequate organ function
- Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- If positive for hepatitis B, has received antiviral therapy for ≥4 weeks and
undetectable viral load prior to randomization
- If positive for hepatitis C, has undetectable viral load at screening
- If positive for human immunodeficiency virus (HIV), has well-controlled HIV on a
stable highly active antiretroviral therapy
Exclusion Criteria
All Cohorts
- Has known hypersensitivity to active substances or their excipients including
previous clinically significant hypersensitivity reaction to treatment with other
monoclonal antibody (mAb)
- History of allogeneic tissue/solid organ transplant
Cohort A only
- Received prior radiotherapy to the index lesion (in-field lesion)
- Participants for whom the primary site of cSCC was anogenital area (penis, scrotum,
vulva, perianal region) are not eligible
Cohort B
- Has had major surgery within 3 weeks prior to first dose of study interventions
- Has preexisting ≥Grade 3 gastrointestinal or non-gastrointestinal fistula
- Has urine protein ≥1 g/24 hours
- Has a left ventricle ejection fraction (LVEF) below the institutional (or local
laboratory) normal range, as determined by multi-gated acquisition (MUGA) or
echocardiogram (ECHO)
- Has radiographic evidence of encasement or invasion of a major blood vessel, or of
intratumoral cavitation
- Has clinically significant cardiovascular disease within 12 months from first dose
of study intervention
Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site ClinicalTrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.
For further information about clinical trials, please contact us at 732-235-7356.